Dr. Öğr. Üyesi ABDURRAHMAN OLĞAÇ

Yayın Ağı

Makaleler 25

1. Target-specific de novo design of drug candidate molecules with graph-transformer-based generative adversarial networks

Unlu A., Cevrim E., Yigit M. G., Sarigun A., Celikbilek H., Bayram O., et al.

NATURE MACHINE INTELLIGENCE , cilt.7, sa.9, 2025 (SCI-Expanded)

2. Discovery of novel microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitors by a structurally inspired virtual screening study

OLĞAÇ A., Jordan P. M., Kretzer C., Werz O., BANOĞLU E.

Journal of Molecular Graphics and Modelling , cilt.136, 2025 (SCI-Expanded)

3. 2-Phenylbenzothiazoles featuring heteroaryl sulfonamide end-capping substructures as developable mPGES-1 inhibitors

Yalcin T., Jordan P. M., OLĞAÇ A., Dahlke P., GÜR MAZ Z. T., BANOĞLU E., et al.

ARCHIV DER PHARMAZIE , cilt.358, sa.1, 2025 (SCI-Expanded, Scopus)

4. Novel Benzimidazole Derivatives as Potent Inhibitors of Microsomal Prostaglandin E₂ Synthase 1 for the Potential Treatment of Inflammation, Pain, and Fever

Ergul A. G., Jordan P. M., Dahlke P., BAL N. B., OLĞAÇ A., Uludag O., et al.

JOURNAL OF MEDICINAL CHEMISTRY , cilt.67, sa.23, ss.21143-21162, 2024 (SCI-Expanded, Scopus)

5. Direct GPCR-EGFR interaction enables synergistic membrane-to-nucleus information transfer

Gekle M., Eckenstaler R., Braun H., OLĞAÇ A., Robaa D., Mildenberger S., et al.

CELLULAR AND MOLECULAR LIFE SCIENCES , cilt.81, sa.1, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

6. Novel 1,3,4-oxadiazole derivatives as highly potent microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors

Gür Maz T., Dahlke P., Ergül A. G., Olğaç A., Jordan P. M., Çalışkan B., et al.

BIOORGANIC CHEMISTRY , cilt.147, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. Substituted 1,2,4-Triazoles as Novel and Selective Inhibitors of Leukotriene Biosynthesis Targeting 5-Lipoxygenase-Activating Protein

Olğaç A., Çapan İ., Dahlke P., Jordan P. M., Werz O., Banoglu E.

ACS OMEGA , cilt.8, sa.34, ss.31293-31304, 2023 (SCI-Expanded, Scopus)

8. Novel indole-pyrazole hybrids as potential tubulin-targeting agents; Synthesis, antiproliferative evaluation, and molecular modeling studies

Hawash M., Ergun S. G., KAHRAMAN D. C., OLĞAÇ A., Hamel E., Cetin-Atalay R., et al.

JOURNAL OF MOLECULAR STRUCTURE , cilt.1285, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition

Turanli S., Ergul A. G., Jordan P. M., Olğaç A., Çalışkan B., Werz O., et al.

ACS OMEGA , cilt.7, sa.41, ss.36354-36365, 2022 (SCI-Expanded, Scopus)

10. Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors.

Çapan İ., Jordan P. M., Olğaç A., Çalışkan B., Kretzer C., Werz O., et al.

ChemMedChem , cilt.17, sa.12, 2022 (SCI-Expanded, Scopus)

11. Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents

Hawash M., KAHRAMAN D. C., OLĞAÇ A., Ergun S. G., Hamel E., Cetin-Atalay R., et al.

Journal of Molecular Structure , cilt.1254, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Identification of novel antiplatelet agents by targeting Glycoprotein VI: A combined virtual screening study

OLĞAÇ S., OLĞAÇ A., YENİCESU İ., ÖZKAN Y.

BIOORGANIC CHEMISTRY , cilt.121, 2022 (SCI-Expanded, Scopus)

13. Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase

Ergül A. G., Maz T. G., Kretzer C., Olğaç A., Jordan P. M., Çalışkan B., et al.

European Journal of Medicinal Chemistry , cilt.231, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Simple heteroaryl modifications in the 4,5-diarylisoxazol-3-carboxylic acid scaffold favorably modulates the activity as dual mPGES-1/5-LO inhibitors with in vivo efficacy

Gurses T., OLĞAÇ A., Garscha U., GÜR MAZ Z. T., BAL N. B., Uludag O., et al.

BIOORGANIC CHEMISTRY , cilt.112, 2021 (SCI-Expanded, Scopus)

15. Mitochondrial Haplogroup Distribution in Elite Turkish Athletes

Kurtuluş M., Günay M., Çelenk Ç., Olğaç A., Kesici T.

Niğde Ömer Halisdemir Üniversitesi Beden Eğitimi ve Spor Bilimleri Dergisi , cilt.14, sa.3, ss.494-502, 2020 (Hakemli Dergi)

16. Discovery of Novel 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors by Exploiting a Multistep Virtual Screening Protocol

OLĞAÇ A., Carotti A., Kretzer C., Zergiebel S., Seeling A., Garscha U., et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING , cilt.60, sa.3, ss.1737-1748, 2020 (SCI-Expanded, Scopus)

17. Ortho versus Meta Chlorophenyl-2,3-Benzodiazepine Analogues: Synthesis, Molecular Modeling, and Biological Activity as AMPAR Antagonists

Qneibi M., Jaradat N., Hawash M., OLĞAÇ A., Emwas N.

ACS OMEGA , cilt.5, sa.7, ss.3588-3595, 2020 (SCI-Expanded, Scopus)

18. The 12(th) AFMC International Medicinal Chemistry Symposium (AIMECS 2019) in Istanbul, Turkey

OLĞAÇ A., Yalcin I., Aki-Yalcin E.

CHEMMEDCHEM , cilt.15, sa.1, ss.162-167, 2020 (SCI-Expanded)

19. Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors

Boccellino M., Donniacuo M., Bruno F., Rinaldi B., Quagliuolo L., Ambruosi M., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.180, ss.637-647, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Structural insight into the optimization of ethyl 5-hydroxybenzo[g] indol-3-carboxylates and their bioisosteric analogues as 5-LO/mPGES-1 dual inhibitors able to suppress inflammation

Bruno F., Errico S., Pace S., Nawrozkij M. B., Mkrtchyan A. S., Guida F., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.155, ss.946-960, 2018 (SCI-Expanded, Scopus)

21. Identification of multi-target inhibitors of leukotriene and prostaglandin E-2 biosynthesis by structural tuning of the FLAP inhibitor BRP-7

GÜR MAZ Z. T., ÇALIŞKAN B., Garscha U., OLĞAÇ A., Schubert U. S., Gerstmeier J., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.150, ss.876-899, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

22. The potential role of in silico approaches to identify novel bioactive molecules from natural resources

Olğaç A., Erdoğan Orhan İ., Banoğlu E.

FUTURE MEDICINAL CHEMISTRY , cilt.9, sa.14, ss.1663-1684, 2017 (SCI-Expanded, Scopus)

23. Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7

Levent S., Gerstmeier J., Olğaç A., Nikels F., Garscha U., Carotti A., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.122, ss.510-519, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)

Banoğlu E., Celikoglu E., Voelker S., Olğaç A., Gerstmeier J., Garscha U., et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.113, ss.1-10, 2016 (SCI-Expanded, Scopus)

25. Synthesis, biological evaluation and molecular docking studies of trans-indole-3-acrylamide derivatives, a new class of tubulin polymerization inhibitors

Baytaş S., Inceler N., Yilmaz A., Olğaç A., Menevse S., Banoğlu E., et al.

BIOORGANIC & MEDICINAL CHEMISTRY , cilt.22, sa.12, ss.3096-3104, 2014 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 63

1. Formulation and Physicochemical Characterization of Interleukin-2 from Various Production Sources

OLĞAÇ S., DEMİRCİ H., DİNLER DOĞANAY G., KULAKMAN C., AKBAŞ Y., OLĞAÇ A., et al.

5th Conference on Innovation in Drug Delivery, Torino, İtalya, 1 - 03 Ekim 2025, (Özet Bildiri)

2. From In Silico to Cell Culture: Formulation Assessment of Human Interleukin-2

OLĞAÇ S., VARAN G., OLĞAÇ A., TEKSİN Z. Ş.

5th Conference on Innovation in Drug Delivery, Torino, İtalya, 1 - 03 Ekim 2025, (Özet Bildiri)

3. FlowProt: Classifier-Guided Flow Matching for Targeted Protein Backbone Generation in the de novo DNA Methyltransfarase Family

TAŞDEMİR A. B., Barlas A. B., OLĞAÇ A., KARACA EREK E., DOĞAN T.

ISMB/ECCB 2025, 20 Temmuz 2025, (Özet Bildiri)

4. Exploring Protease Enzyme Selection for Protein-Structured Active Ingredient Loaded Drug Formulation with Molecular Dynamics Simulations

OLĞAÇ S., OLĞAÇ A., TEKSİN Z. Ş.

21st International Pharmaceutical Technology Symposium, Ankara, Türkiye, 9 - 11 Eylül 2024, (Özet Bildiri)

5. Sanal Tarama Çalışmasında Filtrelenecek Tekil Bileşik Kütüphanelerinin Oluşturulması (CompoundUniqifier)

Dağaşan S., Bıçkı D., Yılmaz E. Y., OLĞAÇ A.

Gazi Üniversitesi I. Öğrenci Projeleri Kongresi ve Bilim Şenliği, Ankara, Türkiye, 13 Mayıs 2024, (Özet Bildiri)

6. Model Eğitiminde ve Model Performansının Belirlenmesinde Kullanmak Üzere Yapı Aktivite Verilerinin Derlenmesi (SARUniqifier)

Bıçkı D., Dağaşan S., Yılmaz E. Y., OLĞAÇ A.

Gazi Üniversitesi I. Öğrenci Projeleri Kongresi ve Bilim Şenliği, Ankara, Türkiye, 13 Mayıs 2024, (Özet Bildiri)

7. Unveiling Novel Leukotriene B4 Receptor (BLT1R) Antagonists and Their Binding Characteristics Through Combined Strategies

OLĞAÇ A., CAROTTI A., BANOĞLU E.

Gordon Research Conference on Computer Aided Drug Design, Vermont, Amerika Birleşik Devletleri, 16 - 21 Temmuz 2023, (Özet Bildiri)

8. A Tale of Two 5-Lipoxygenase Activating Protein (FLAP) Inhibitors

OLĞAÇ A., TURANLI S., ÇAPAN İ., Dahlke P., ERGÜL A. G., Jordan P. M., et al.

Gordon Research Seminar on Computer Aided Drug Design, Vermont, Amerika Birleşik Devletleri, 15 - 16 Temmuz 2023, (Özet Bildiri)

9. Screening and assessment of excipients for nanoemulsion formulationsof interleukin-2 with computational studies

Olğaç S., Olğaç A., Teksin Z. Ş.

EUFEPS Annual Meeting 2023, Lisbon, Portekiz, 31 Mayıs - 02 Haziran 2023, (Özet Bildiri)

10. Screening and Assessment of Excipients for Nanoemulsion Formulations of İnterleukin-2 with Computational Studies

Olğaç S., Olğaç A., Teksin Z. Ş.

EUFEPS Annual Meeting 2023, Lisbon, Portekiz, 31 Mayıs - 02 Haziran 2023, (Özet Bildiri)

11. A Tale of Two Diverse Sets of Novel 5-Lipoxygenase Activating Protein (FLAP) Inhibitors

OLĞAÇ A., TURANLI S., ÇAPAN İ., Dahlke P., ERGÜL A. G., Jordan P. M., et al.

International Multidisciplinary Symposium on Drug Research and Development (DRD) 2023, İzmir, Türkiye, 04 Mayıs 2023, (Özet Bildiri)

12. A journey from selective FLAP inhibitor to selective mPGES-1 inhibitor: A new therapeutic modality for reducing inflammation and pain

BANOĞLU E., ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., OLĞAÇ A., JORDAN P. M., et al.

8th International Bahçeşehir University (BAU) Drug Design Congress, İstanbul, Türkiye, 15 - 17 Aralık 2022, (Özet Bildiri)

13. Disease Centric Large Scale De Novo Design of Drug Candidate Molecules with Graph Generative Deep Adversarial Networks

Ünlü A., Sarıgün A., Candaş E., Ataş H., OLĞAÇ A., RİFAİOĞLU A. S., et al.

15th International Symposium on Health Informatics and Bioinformatics (HiBiT'22), Mersin, Türkiye, 20 - 22 Ekim 2022, (Özet Bildiri)

14. Identification of Novel Microsomal Prostaglandin E2 Type 1 (mPGES-1) Inhibitors by Conducting Structure-based Virtual Screening

Olğaç A., Carotti A., Jordan P. M., Kretzer C., Werz O., Banoğlu E.

International Bioinformatics Conference (IBC 2022), Tanjah, Fas, 8 - 09 Ekim 2022, ss.17, (Özet Bildiri)

15. IDENTIFICATION OF NOVEL MICROSOMAL PROSTAGLANDIN E2 TYPE 1 (mPGES-1) INHIBITORS BY CONDUCTING STRUCTURE-BASED VIRTUAL SCREENING

OLĞAÇ A., Carotti A., Jordan P. M., Kretzer C., Werz O., BANOĞLU E.

23rd European Symposium on Quantitative Structure-Activity Relationship (EuroQSAR), Heidelberg, Almanya, 26 Eylül 2022, (Özet Bildiri)

16. IDENTIFICATION OF NOVEL SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) ACTIVE SITES BY MOLECULAR DYNAMICS

Ekinci K., Olğaç A., Akı Yalçın E. E.

23rd European Symposium on Quantitative Structure-Activity Relationship (EuroQSAR), Heidelberg, Almanya, 26 Eylül 2022, (Özet Bildiri)

17. Disease Centric Large Scale De Novo Design of Drug Candidate Molecules with Graph Generative Deep Adversarial Networks

Ünlü A., Sarıgün A., Ataş H., Candaş E., OLĞAÇ A., RİFAİOĞLU A. S., et al.

7th European Student Council Symposium, Barcelona, İspanya, 18 Eylül 2022, (Özet Bildiri)

18. Novel Microsomal Prostaglandin E2 Synthase-1 (MPGES-1) Inhibitors as a New Modality To Treat Inflammation

ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., KRETZER C., OLĞAÇ A., JORDAN P. M., et al.

XXVll EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2022), Nice, Fransa, 4 - 08 Eylül 2022, (Özet Bildiri)

19. SELECTIVE OR DUAL INHIBITORS OF INFLAMMATORY PGE2 AND LTB4 BIOSYNTHESIS BY TARGETING mPGES-1 AND FLAP TO INTERVENE WITH INFLAMMATORY DEREGULATION

BANOĞLU E., ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., OLĞAÇ A., WERZ O.

The Sixth International Symposium on Pharmaceutical and Biomedical Sciences (ISPBS-6), Gaziantep, Türkiye, 26 - 28 Mayıs 2022, (Özet Bildiri)

20. Discovery of Novel Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors: A New Modality to Treat Inflammation

Banoğlu E., Çalışkan B., Ergül A. G., Gür Maz Z. T., Kretzer C., Olğaç A., et al.

10th International Drug Chemistry Conference, Antalya, Türkiye, 10 - 13 Mart 2022, (Özet Bildiri)

21. Molecular Docking, Design, Synthesis and Biological Evaluation Of Novel Benzodioxole Derivatives On Various Biological Targets

Hawash M., OLĞAÇ A.

5th Russian Medchem-Russia 2021 Conference (MedChem-Russia 2021), Volgograd, Rusya, 05 Ekim 2021, (Özet Bildiri)

22. Computational Insights into the Binding Pattern of Microsomal Prostaglandin E-2 Synthase Type 1 Inhibitors

Olğaç A., Banoğlu E.

3rd International Gazi Pharma Symposium Series (GPSS-2021), Ankara, Türkiye, 8 - 10 Eylül 2021, ss.77, (Özet Bildiri) Sürdürülebilir Kalkınma

23. Structure-Guided Selection of Suitable Nanoemulsion Formulation Components for a Recombinant Form of Human Interleukin-2 (Aldesleukin)

Olğaç S., Olğaç A., İnceçayır T., Teksin Z. Ş.

3rd International Gazi Pharma Symposium Series (GPSS-2021), Ankara, Türkiye, 8 - 10 Eylül 2021, (Özet Bildiri)

24. Investigation of the activation mechanisms of natural clotting processes by highly deacetylated chitosan

Elçi S. D., BOLELLİ K., Hidayat A. N., OLĞAÇ A., Javornik U., BELEN APAK F. B., et al.

8th International Drug Chemistry Conference, Antalya, Kemer, Türkiye, 27 Şubat - 01 Mart 2020, (Özet Bildiri)

25. Discovery of Multitarget Inhibitors in the Arachidonic Acid Pathway by Targeting FLAP/5-LO/mPGES-1 for Intervention with Inflammatory Deregulation

BANOĞLU E., ÇALIŞKAN B., GÜR MAZ Z. T., OLĞAÇ A., Garscha U., Werz O.

8th International Drug Chemistry Conference, Antalya, Türkiye, 27 Şubat - 01 Mart 2020, (Özet Bildiri)

26. An in silico Investigation of the Activation Mechanisms of Clotting Processes by Highly Deacetylated Oligomeric Chitosan

Elçi S. D., Hidayat A. N., OLĞAÇ A., AKI YALÇIN E. E.

Asian Federation for Medicinal Chemistry (AFMC) 12th International Symposium, Ankara, Türkiye, 8 - 11 Eylül 2019, (Özet Bildiri)

27. Virtual Screening to Discover Drug Candidates Targeting Platelet Receptors

OLĞAÇ S., OLĞAÇ A., YENİCESU İ., ÖZKAN Y.

Asian Federation of Medicinal Chemistry (AFMC) 12th International Symposium, İstanbul, Türkiye, 8 - 11 Eylül 2019, (Özet Bildiri)

28. Virtual Screening for Small Molecule Inhibitors of Glycoprotein VI (GPVI)

OLĞAÇ S., OLĞAÇ A., ÖZKAN Y.

4th European Platelet Network (EUPLAN), 19 - 21 Eylül 2018, (Özet Bildiri)

29. DISCOVERY OF NOVEL 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS BY VIRTUAL SCREENING ANDPHARMACOLOGICAL EVALUATION

OLĞAÇ A., CAROTTI A., Garscha U., Werz O., Macchiarulo A., BANOĞLU E.

22nd European Symposium on Quantitative Structure-Activity RelationshipsTranslational and Health Informatics: Implications for Drug Discovery, 16 - 20 Eylül 2018, (Özet Bildiri)

30. EVOLUTION OF SELECTIVE FLAP INHIBITOR BRP-7 INTO MULTI-TARGET INHIBITOR OF FLAP, 5-LO AND MPGES-1 IN THE ARACHIDONIC ACID PATHWAY

GÜR MAZ Z. T., ÇALIŞKAN B., OLĞAÇ A., GERSTMEIER J., GARSCHA U., WERZ O., et al.

EFMC International Symposium on Medicinal Chemistry, Ljubljana, Slovenya, 2 - 06 Eylül 2018, ss.231, (Özet Bildiri)

31. PROTEIN-LIGAND INTERACTION ANALYSIS THROUGH DOCKING AND MOLECULAR DYNAMIC SIMULATIONS OF KNOWN 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS

OLĞAÇ A., CAROTTI A., Macchiarulo A., BANOĞLU E.

RICT 2018 Interfacing Chemical Biology and Drug Discovery 54th International Conference on Medicinal Chemistry, Strasbourg, Fransa, 4 - 06 Temmuz 2018, (Özet Bildiri)

32. In Vitro Antiplatelet Studies on Virtually Discovered GPVI Drug Candidates

OLĞAÇ S., Olgaç A., ÖZKAN Y.

12th International Symposium on Pharmaceutical Sciences (ISOPS), 26 - 29 Haziran 2018, (Özet Bildiri)

33. SANAL TARAMA VE FARMAKOLOJİK DEĞERLENDİRME YOLUYLA YENİ 5-LİPOKSİJENAZ AKTİVE EDİCİ PROTEİN (FLAP) İNHİBİTÖRÜ BİLEŞİKLERİN KEŞFİ

OLĞAÇ A., CAROTTI A., Garscha U., Werz O., Macchiarulo A., BANOĞLU E.

V. ULUSAL FARMASÖTİK KİMYA KONGRESİ, Erzurum, Türkiye, 28 Nisan - 01 Mayıs 2018, (Özet Bildiri)

34. ANTİLÖKOTRİEN ETKİLİ 1,2,5-TRİSÜBSTİTÜEBENZİMİDAZOL TÜREVLERİNİN GELİŞTİRİLMESİ ÜZERİNDE YAPILAN ÇALIŞMALAR

GÜR MAZ Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., WERZ O., et al.

V. ULUSAL FARMASÖTİK KİMYA KONGRESİ, Erzurum, Türkiye, 28 Nisan - 01 Mayıs 2018, (Özet Bildiri)

35. Cloud-Based High Performance Virtual Screening in Novel Drug Discovery

OLĞAÇ A., Möller S.

WG MC Meeting Fontainebleau (France), Fontainebleau, Fransa, 19 - 20 Mart 2018, (Özet Bildiri)

36. Discovery and Development of Novel Anti-cancer and Anti-inflammatory Compounds: Medicinal Chemistry Challenges

BANOĞLU E., ÇALIŞKAN B., GÜR MAZ Z. T., OLĞAÇ A., İBİŞ K., Akhan Güzelcam E., et al.

The 4th International Symposium on Pharmaceutical and Biomedical Sciences, Kumamoto, Japonya, 17 Mart 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

37. Discovery of Novel 5-Lipoxygenase Activating Protein (FLAP) Inhibitors by Virtual Screening

OLĞAÇ A., CAROTTI A., GERSTMEIER J., GARSCHA U., WERZ O., MACCHIARULO A., et al.

2nd International Gazi Pharma Symposium Series, 11 - 13 Ekim 2017, (Özet Bildiri)

38. Investigation of Novel Platelet Receptor GPVI Inhibitor Candidates

OLĞAÇ S., OLĞAÇ A., ÖZKAN Y.

2nd International Gazi Pharma Symposium Series, 11 - 13 Ekim 2017, (Özet Bildiri)

39. Developing Multi-target Inhibitors of Arachidonic Acid Pathway Based on the FLAP Inhibitor BRP-7

GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., WERZ O., et al.

2nd International Gazi Pharma Symposium Series, 11 - 13 Ekim 2017, (Özet Bildiri)

40. Discovery of Dual FLAP/mPGES-1 Inhibitors for Intervention with Inflammatory Diseases:Medicinal Chemistry Challenges

BANOĞLU E., ÇALIŞKAN B., GÜR Z. T., OLĞAÇ A.

Turkish Japanese Workshop on Bioorganic Medicinal Chemistry Natural Products, 14 Eylül 2017, (Özet Bildiri)

41. Discovery of Novel 5-Lipoxygenase Activating Protein (FLAP) Inhibitors by Combined Ligand- and Structure-Based Virtual Screening

OLĞAÇ A., CAROTTI A., GERSTMEIER J., GARSCHA U., WERZ O., MACCHIARULO A., et al.

EFMC-ASMC’xx17 EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry, 27 - 31 Ağustos 2017, (Özet Bildiri)

42. Bioisosteric Tuning of FLAP Inhibitor BRP-7 Towards a More Potent Antiinmlammatory Agent with Multiligand Inhibitor Properties in the Arachidonic Acid (AA) Pathway

GÜR Z. T., ÇALIŞKAN B., OLĞAÇ A., GERSTMEIER J., GARSCHA U., WERZ O., et al.

EFMC-ASMC’xx17 EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry, 27 - 31 Ağustos 2017, (Özet Bildiri)

43. Araşidonik asit yolağında çoklu ligand (FLAP/5-LO/mPGES-1) özellikte inhibitör etkili BRP-7 türevlerinin geliştirilmesi

BANOĞLU E., GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., et al.

1. Anadolu Üniversitesi Eczacılık Sempozyumu, Eskişehir, Türkiye, 1 - 02 Haziran 2017, ss.10, (Özet Bildiri)

44. Structure based virtual screaning to discover platelet GPVI inhibitors

OLĞAÇ S., olgac A., ÖZKAN Y.

The 3rd EUPLAN conference, 21 - 23 Eylül 2016, (Özet Bildiri)

45. Structure Based Virtual Screening to Discover Platelet GPVI Inhibitors

OLĞAÇ S., OLĞAÇ A., ÖZKAN Y.

Third European Platelet Network (EUPLAN) Conference 2016, Bad Homburg vor der Höhe, Almanya, 21 - 23 Eylül 2016, (Özet Bildiri)

46. Screening FDA Approved Drugs to Discover Potent GPVI Inhibitors

OLĞAÇ S., OLĞAÇ A., ÖZKAN Y.

XXIV National Meeting in Medicinal Chemistry, Perugia, İtalya, 11 - 14 Eylül 2016, (Özet Bildiri)

47. Structure Guided Design of Novel Isoxazole and Benzimidazole Derivatives as Potent 5 Lipoxygenase 5 LO and 5 LO Activating Protein FLAP Inhibitors

OLĞAÇ A., CAROTTI A., WERZ O., BANOĞLU E., MACCHIARULO A.

XXIV National Meeting in Medicinal Chemistry, Perugia, İtalya, 11 - 14 Eylül 2016, (Özet Bildiri)

48. Evias Web Services Cloud Based Drug Discovery Platform

OLĞAÇ A., BUDAK G., OLĞAÇ S., NUTI R., CAROTTI A., BANOĞLU E.

21st European Symposium on Quantitative Structure-Activity Relationship, Verona, İtalya, 4 - 08 Eylül 2016, (Özet Bildiri)

49. Novel BRP 7 Derivatives Targeting FLAP Potent Inhibitors of Leukotriene Biosynthesis

GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., GARSCHA U., OLĞAÇ A., WERZ O., et al.

3rd EFMC Young Medicinal Chemist Symposium, Manchester, Birleşik Krallık, 1 - 02 Eylül 2016, (Özet Bildiri)

50. Exploratıon of the Chemıcal Space Around C 5 Posıtıon Of The Benzimidazole Nucleus in BRP 7 Towards More Potent Inhıbıtors of Human 5 Lıpoxygenase Actıvatıng Proteın FLAP

GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., NIKELS F., WERZ O., et al.

EFMC International Symposium on Medicinal Chemistry 2016, Manchester, Birleşik Krallık, 28 Ağustos - 01 Eylül 2016, (Özet Bildiri)

51. Discovery of 4 5 Diarylisoxazol 3 Carboxylic Acid Skeleton as a Novel Chemotype for Inhibition of 5 Lipoxygenase Activating Proteın FLAP

ÇALIŞKAN B., ÇELİKOĞLU E., GERSTMEIER J., VOELKER S., GARSCHA U., OLĞAÇ A., et al.

EFMC International Symposium on Medicinal Chemistry 2016, Manchester, Birleşik Krallık, 28 Ağustos - 01 Eylül 2016, (Özet Bildiri)

52. Cloud Based Drug Discovery Platforms

OLĞAÇ A.

IBSS'2016 Resources and Techniques in Computational Drug Discovery, TANCA, Fas, 23 - 26 Mayıs 2016, (Özet Bildiri)

53. Structure Guided Design of Novel Isoxazole and Benzimidazole Derivatives as Potent FLAP and 5 LO Inhibitors

OLĞAÇ A., CAROTTI A., BANOĞLU E., MACCHIARULO A.

IBSS'2016 Resources and Techniques in Computational Drug Discovery, Fas, 23 - 26 Mayıs 2016, (Özet Bildiri)

54. Hands on Evias Cloud Virtual Screening Module

OLĞAÇ A., BUDAK G., NUTI R.

IBSS'2016 Resources and Techniques in Computational Drug Discovery, TANCA, Fas, 23 - 26 Mayıs 2016, (Özet Bildiri)

55. Evias Cloud Based Drug Discovery Platform

OLĞAÇ A., BUDAK G., OLĞAÇ S., NUTI R., CAROTTI A., BANOĞLU E.

High-Performance Modelling and Simulation for Big Data Applications - Management Committee & Working Group Meeting, Dublin, İrlanda, 25 - 26 Nisan 2016, (Özet Bildiri)